NO20053928L - Fremgangsmate for a fremstille ondansetron og intermediater derav. - Google Patents
Fremgangsmate for a fremstille ondansetron og intermediater derav.Info
- Publication number
- NO20053928L NO20053928L NO20053928A NO20053928A NO20053928L NO 20053928 L NO20053928 L NO 20053928L NO 20053928 A NO20053928 A NO 20053928A NO 20053928 A NO20053928 A NO 20053928A NO 20053928 L NO20053928 L NO 20053928L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- intermediates
- producing
- salt
- compound
- Prior art date
Links
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
- 229960005343 ondansetron Drugs 0.000 title 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- AMLYRCOEFHJSFS-UHFFFAOYSA-N carbazol-1-one Chemical compound C1=CC=C2C3=CC=CC(=O)C3=NC2=C1 AMLYRCOEFHJSFS-UHFFFAOYSA-N 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000002798 polar solvent Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Impact Printers (AREA)
- Machines For Manufacturing Corrugated Board In Mechanical Paper-Making Processes (AREA)
- Optical Couplings Of Light Guides (AREA)
- Footwear And Its Accessory, Manufacturing Method And Apparatuses (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Forging (AREA)
- Pressure Welding/Diffusion-Bonding (AREA)
Abstract
Oppfinnelsen vedrører en fremgangsmåte for å produsere en forbindelse med formel (1), hvori et karbazolon med formel (2), formaldehyd eller en formaldehydforløper, et amin med formel (3) eller et salt derav hvori R1 og R2 hver uavhengig representerer en C1- til C4-alkylgruppe eller sammen med nitrogenatomet danner de en 5- eller 6-medlemsring, og et imidazol med formel (5) eller et salt derav reageres ved høy temperatur i et ikke-vandig polart løsemiddel og i nærvær av et vannbindemiddel for å danne forbindelsen med formel (1).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44205503P | 2003-01-24 | 2003-01-24 | |
PCT/EP2003/002743 WO2004065381A1 (en) | 2003-01-24 | 2003-03-14 | Process for making ondansetron and intermediates thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20053928D0 NO20053928D0 (no) | 2005-08-23 |
NO20053928L true NO20053928L (no) | 2005-10-24 |
Family
ID=23755350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20053928A NO20053928L (no) | 2003-01-24 | 2005-08-23 | Fremgangsmate for a fremstille ondansetron og intermediater derav. |
Country Status (10)
Country | Link |
---|---|
US (1) | US7041834B2 (no) |
EP (1) | EP1585744B1 (no) |
AT (1) | ATE344258T1 (no) |
AU (2) | AU2003222763A1 (no) |
DE (1) | DE60309511T2 (no) |
FR (1) | FR2850381B1 (no) |
GB (1) | GB2398071B (no) |
NL (1) | NL1022894C2 (no) |
NO (1) | NO20053928L (no) |
WO (1) | WO2004065381A1 (no) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100566317B1 (ko) * | 2003-10-16 | 2006-03-30 | 주식회사유한양행 | 카바졸온 유도체 제조 방법 |
US7696356B2 (en) * | 2004-08-17 | 2010-04-13 | Taro Pharmaceutical Industries Limited | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom |
EP1828141A4 (en) * | 2004-10-26 | 2009-04-01 | Ipca Lab Ltd | STAINING METHOD FOR PREPARING THE ANTIEMETIC 1,2,3,9-TETRAHYDRO-9-METHYL-3 - [(2-METHYL) -1H-IMIDAZOLE-1-YL) METHYL] -4H-CARBAZOLE-4-ON |
EP2273880B1 (en) * | 2008-04-28 | 2014-12-31 | Zogenix, Inc. | Novel formulations for treatment of migraine |
CN109020871A (zh) * | 2018-10-03 | 2018-12-18 | 淮安安莱生物科技有限公司 | 一种昂丹司琼杂质a的制备方法 |
CN115677561B (zh) * | 2022-11-01 | 2024-04-05 | 常州兰陵制药有限公司 | 一种1,2,3,4-四氢-9-甲基-4h-咔唑酮及其合成方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR920003064B1 (ko) * | 1984-01-25 | 1992-04-13 | 글락소 그룹 리미티드 | 헤테로시클릭 화합물의 제조방법 |
US4695578A (en) * | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
CN1107474A (zh) | 1994-03-31 | 1995-08-30 | 北京四达生物技术研究所 | 一种四氢咔唑酮衍生物的制备方法 |
CN1040644C (zh) | 1994-04-29 | 1998-11-11 | 北京天衡时代科技集团 | 一种4-氢咔唑酮衍生物的制备方法 |
CN1035672C (zh) * | 1994-08-08 | 1997-08-20 | 上海医科大学 | 3-(甲基咪唑基)-甲基-四氢-咔唑酮新的制备方法 |
WO1999064046A1 (en) * | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-ht3 receptors |
TR200401460T3 (no) * | 2001-01-11 | 2004-08-23 | Teva Pharmaceutical Industries Ltd. |
-
2003
- 2003-03-04 GB GB0304924A patent/GB2398071B/en not_active Expired - Fee Related
- 2003-03-11 NL NL1022894A patent/NL1022894C2/nl not_active IP Right Cessation
- 2003-03-14 WO PCT/EP2003/002743 patent/WO2004065381A1/en not_active Application Discontinuation
- 2003-03-14 EP EP03718688A patent/EP1585744B1/en not_active Expired - Lifetime
- 2003-03-14 AU AU2003222763A patent/AU2003222763A1/en not_active Abandoned
- 2003-03-14 AT AT03718688T patent/ATE344258T1/de not_active IP Right Cessation
- 2003-03-14 DE DE60309511T patent/DE60309511T2/de not_active Expired - Fee Related
- 2003-04-03 FR FR0304140A patent/FR2850381B1/fr not_active Expired - Fee Related
- 2003-04-08 AU AU2003203585A patent/AU2003203585A1/en not_active Abandoned
-
2004
- 2004-01-23 US US10/762,552 patent/US7041834B2/en not_active Expired - Fee Related
-
2005
- 2005-08-23 NO NO20053928A patent/NO20053928L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
GB2398071A (en) | 2004-08-11 |
FR2850381B1 (fr) | 2006-06-09 |
NO20053928D0 (no) | 2005-08-23 |
EP1585744B1 (en) | 2006-11-02 |
DE60309511T2 (de) | 2007-06-28 |
FR2850381A1 (fr) | 2004-07-30 |
ATE344258T1 (de) | 2006-11-15 |
US20040181076A1 (en) | 2004-09-16 |
AU2003203585A1 (en) | 2004-08-12 |
AU2003222763A1 (en) | 2004-08-13 |
NL1022894C2 (nl) | 2004-07-28 |
GB2398071B (en) | 2006-06-07 |
US7041834B2 (en) | 2006-05-09 |
GB0304924D0 (en) | 2003-04-09 |
DE60309511D1 (de) | 2006-12-14 |
EP1585744A1 (en) | 2005-10-19 |
WO2004065381A1 (en) | 2004-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20052781L (no) | Forbindelser og prosesser | |
NO20053928L (no) | Fremgangsmate for a fremstille ondansetron og intermediater derav. | |
YU44898A (sh) | Postupak za dobijanje magnezijumove soli supstituisanog heterocikličnog sulfinila | |
EA200701470A1 (ru) | Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений | |
CA2461060A1 (en) | Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof | |
HUP0000524A2 (hu) | Eljárás tiazolszármazékok és intermedierjeik előállítására | |
DK1858878T3 (da) | Konvertering af 2-pyrazoliner til pyrazoler ved hjælp af brom | |
Gong et al. | Construction of fluorescence-tunable pyrido-fused benzimidazoles via direct intramolecular C–H amination under transition-metal-free conditions | |
JP2009502802A5 (no) | ||
Ou et al. | Preparation of homoallylic amines via a three-component coupling process | |
CN107501153B (zh) | 一种2-(2,2,2-三氟乙基)-3-芳基-2h-氮杂丙烯啶化合物的制备方法 | |
WO2010104027A1 (ja) | チアゾール誘導体およびその製造方法 | |
CN103613593B (zh) | 一种酰胺基脲衍生物的制备方法 | |
CN108299303B (zh) | 一种四芳基吡唑类化合物的合成新方法 | |
NO20055991L (no) | Fremgangsmate for syntetisering av heterocykliske forbindelser | |
DK0786459T3 (da) | Fremgangsmåde til fremstilling af en heterobicyklisk alkoholenantiomer | |
NO20070610L (no) | Fremgangsmate for fremstilling av synteseintermediater anvendelige ved fremstilling av pyrazolforbindelser. | |
CN108191862B (zh) | 4-羟基-2-取代吡唑并吡啶类化合物的合成方法 | |
CA2649506A1 (en) | 2-alkenyl-3-aminothiophene derivative and process for producing thereof | |
TW200730495A (en) | Process for producing 2-oxindole compound | |
JP6499606B2 (ja) | 含硫黄環化化合物の製造方法 | |
Alam et al. | POCl3 Mediated Staudinger Reaction of Imines with Ketenes: Synthesis of Monocyclic β-Lactam and 1, 3-Oxazinone Derivatives | |
KR790001653B1 (ko) | S-트리아졸로[3, 4-b] 벤조티아졸류의 제조방법 | |
Al-Zaydi et al. | Functionally substituted 1-alkylbenzotriazoles in heterocyclic synthesis: Synthesis and reactivity of benzotriazol-1-yl amides | |
Maettner et al. | Synthesis and reactions of 1, 2, 3-triazinium salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |